Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 juin 2017 07h00 HE | Source: FibroGen, Inc.

European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology

SAN FRANCISCO, June 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic...
09 mai 2017 16h02 HE | Source: FibroGen, Inc.

FibroGen Reports First Quarter 2017 Financial Results

SAN FRANCISCO, May 09, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided...
03 mai 2017 07h00 HE | Source: FibroGen, Inc.

FibroGen to Report First Quarter Financial Results on May 9, 2017

SAN FRANCISCO, May 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter financial results on...
06 avr. 2017 07h00 HE | Source: FibroGen, Inc.

FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock

SAN FRANCISCO, April 06, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the company has priced an underwritten follow-on...
31 mars 2017 07h05 HE | Source: FibroGen, Inc.

FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS

SAN FRANCISCO, March 31, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration...
30 mars 2017 07h00 HE | Source: FibroGen, Inc.

Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

SAN FRANCISCO, March 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from two Phase 2 studies in China of...
01 mars 2017 16h02 HE | Source: FibroGen, Inc.

FibroGen Reports Fiscal 2016 Financial Results

SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...
22 févr. 2017 22h37 HE | Source: FibroGen, Inc.

FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017

SAN FRANCISCO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the year ended...
03 févr. 2017 11h06 HE | Source: FibroGen, Inc.

FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy

SAN FRANCISCO, Feb. 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc., (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from the company’s open-label,...
30 janv. 2017 07h00 HE | Source: FibroGen, Inc.

FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China

SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....

Page précédente